Ceva and ProBioGen Signs Multi-product License Agreement
News Mar 16, 2012
Ceva Santé Animale (Ceva) and ProBioGen have announced the signature of a multi-product license agreement for the use of ProBioGen’s AGE1.CR® avian cell line in the industrial production of viral animal vaccines.
In a preceding pilot study Ceva evaluated the technology, which allows cells to grow rapidly and in high cell densities in ProBioGen’s proprietary chemically defined medium.
Master cell banking for one viral vaccine strain has been completed and further development projects are underway.
Volker Sandig, Chief Scientific Officer of ProBioGen, is convinced that, “this agreement is the result of an excellent collaboration and is based on a mutual focus on technologically optimized biopharmaceutical manufacturing. We are pleased that Ceva as an expert vaccine producer decided to work with us on our AGE1.CR® cell line. We are looking very much forward to further broaden the cooperation between our scientists in accomplishing additional goals.”
Marc Prikazsky, Ceva’s Chairman and CEO said “This type of scientific and industrial partnership with ProBioGen is an excellent example of how we hope to develop collaboration with genuinely innovative partners in our mission to go ’Together, beyond animal health’.”
An undisclosed number of animal vaccines are to be evaluated on the AGE1.CR® cell line. The commercial license includes milestone and royalty payments. Financial details were not disclosed.
Batavia Biosciences Teams Up with International Consortium to Support Polio EradicationNews
Batavia Biosciences announces its partnership with an international consortium coordinated by PATH aiming to develop and manufacture safer novel oral poliovirus vaccines (nOPV).READ MORE
Innate Immune Cells Reprogrammed to Fight TuberculosisNews
A cure has eluded scientists for more than a century but, now, a Montreal team of researchers may have discovered a new weapon to combat this global killer. The team is re-programing - or 'training' - immune cells to kill TB. These groundbreaking findings are published online today in the journal Cell.READ MORE
Antibiotic Micro-beads Fight Infection in Joint ReplacementsNews
More than 1 million people undergo total joint replacements each year, and nearly 10,000 will develop infections. To reduce this infection risk, an orthopedic surgeon has created small antibiotic beads that are implanted with the new joint to slowly release medicine for several weeks.READ MORE